United Kingdom PCSK9-Targeted Therapy Market Size, Share, Growth, and Industry Analysis, By Drug Type / Modality (Monoclonal Antibodies (mAbs) Alirocumab Evolocumab, siRNA-based Therapies Inclisiran, Gene Editing and Other Novel Modalities CRISPR-based approaches Antisense oligonucleotides (ASOs) ), By Indication  (Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD), Homozygous Familial Hypercholesterolemia (HoFH), Hyperlipidemia (Non-FH) ) and Forecast, 2026-2034

United Kingdom PCSK9-Targeted Therapy Market Trends

Long-Interval RNA Therapy and Oral/One-Time Platforms Reshape Treatment

Technology is shifting from injections every 2–4 weeks toward less-frequent or non-injectable regimens. Inclisiran uses 284-mg dosing with 6-month maintenance intervals, while alirocumab can be administered at 75–150 mg every 2 weeks or 300 mg every 4 weeks. England’s pharmaceutical dispensing infrastructure processed 1.30 billion community items in 2025/26, including 78 million atorvastatin items, illustrating the scale of the lipid-management channel.

Oral and gene-editing approaches could materially change adoption. Merck’s once-daily enlicitide produced a 55.8% LDL-C reduction at week 24, reaching 59.7% in a post-hoc analysis, with ≥97% adherence. Lilly’s VERVE-102 delivered PCSK9 reductions of 51%–88% and LDL-C reductions up to 62% after a single infusion in a 35-participant Phase 1b analysis, with durability observed up to 18 months.

United Kingdom PCSK9-Targeted Therapy Market Drivers

Large Cardiovascular Risk Pool Supports United Kingdom PCSK9-Targeted Therapy Market Growth

Approximately 7.6 million UK residents live with heart or circulatory disease, while cardiovascular disease causes around 25% of national deaths and carries approximately £12 billion in annual healthcare costs plus £28 billion in wider economic costs. NHS England’s inclisiran agreement targeted 300,000 patients over 3 years and estimated prevention of 55,000 heart attacks and strokes and 30,000 deaths over a decade, establishing a sizeable treated population for advanced LDL-C lowering.

United Kingdom PCSK9-Targeted Therapy Market Restraints

Specialty-Drug Economics and Injectable Administration Constrain Access

List-price economics remain significant despite confidential NHS discounts. NICE records inclisiran at £1,987.36 per 284-mg pack, while alirocumab was listed at £168 per 75-mg or 150-mg pen and £4,383 annually under 2-week dosing. These costs contrast with a high-volume NHS environment processing 1.30 billion community prescription items annually and £11.6 billion in expenditure, intensifying cost-effectiveness scrutiny for specialty lipid therapies.

United Kingdom PCSK9-Targeted Therapy Market Opportunities

Oral PCSK9 Inhibition and One-Time Editing Expand the Addressable Population

AstraZeneca’s once-daily 30-mg AZD0780 achieved a 50.7% placebo-adjusted LDL-C reduction after 12 weeks in PURSUIT, while Merck’s enlicitide delivered 55.8%–59.7% reductions at week 24. Meanwhile, VERVE-102 generated up to 88% PCSK9 and 62% LDL-C reductions after one infusion, potentially shifting treatment from chronic administration toward durable intervention.

Challenges in United Kingdom PCSK9-Targeted Therapy Market

Identification, Eligibility and Long-Term Outcomes Remain Critical

The clinical funnel spans 7.6 million people with heart or circulatory disease against an initial 300,000-patient inclisiran programme, illustrating selective eligibility. Novel therapies also require long-duration evidence: VERVE-102’s 2026 analysis covered 35 participants with follow-up up to 18 months, whereas established NHS pathways must manage treatment over many years.

United Kingdom PCSK9-Targeted Therapy Market Segmentation

The supplied 2026 data show mAbs at 47.2%, siRNA at 30.1% and novel modalities at 22.7%. By indication, HeFH represents approximately 43.9%, ASCVD 27.7%, HoFH 16.6% and non-FH hyperlipidemia 11.8%.

By Drug Type / Modality

Monoclonal antibodies—principally evolocumab and alirocumab—lead at USD 255.05 million in 2026 and are projected at USD 583.97 million by 2034, recording the highest modality CAGR of 10.91%.

siRNA therapies rise from USD 162.69 million to USD 363.99 million at 10.59% CAGR, while gene editing and other novel modalities increase from USD 122.88 million to USD 273.72 million at 10.53%. Thus, mAbs remain both the largest and fastest-growing supplied modality.

By Indication

HeFH is the largest indication at USD 237.60 million in 2026, reaching USD 542.85 million in 2034 at 10.88% CAGR. Its 2025 contribution was 43.9% of indication value.

ASCVD advances from USD 149.58 million to USD 338.80 million at 10.76% CAGR; non-FH hyperlipidemia records 10.80%, while HoFH records 10.28%. The supplied indication total is USD 540.66 million for 2026 and USD 1,222.76 million for 2034.

By Route of Administration

Commercially established PCSK9 products in the specified segmentation are predominantly subcutaneous, including inclisiran and the mAbs; oral therapy remains pipeline-stage. Enlicitide’s Phase 3 programme demonstrated 55.8%–59.7% LDL-C lowering with ≥97% adherence.

Intravenous administration is emerging through gene editing: VERVE-102 is delivered as a single infusion and achieved up to 62% LDL-C reduction. No supplied market-size or CAGR figures were provided for route subsegments, so none are fabricated.

By Distribution Channel

Hospital, retail/community and online-enabled pharmacy channels form the distribution structure. England dispensed 1.30 billion community prescription items worth £11.6 billion in 2025/26, representing 3% volume and 4% cost increases year over year.

Digitalisation supports prescription routing, while NHS England targeted 95% of trusts to implement or upgrade electronic patient records by March 2026. No validated channel-specific PCSK9 value or CAGR was supplied.

By Patient Type

Secondary prevention is central to NHS adoption: the initial population-health programme targeted 300,000 high-cholesterol patients with previous cardiovascular disease over 3 years, with potential expansion toward nearly 500,000 patients.

Primary-prevention high-risk and statin-intolerant populations broaden the future pool. Inclisiran’s authorisation includes statin-intolerant patients, while the 2025 VICTORION-Mono study enrolled 350 participants and showed a 47.9% LDL-C reduction versus placebo at day 150.

United Kingdom PCSK9-Targeted Therapy Market Counties Outlook

England: Using mid-2024 population as an allocation proxy, England represents roughly 84.6% of the UK pool, implying approximately USD 413 million of the supplied 2025 total. Its population expanded 1.2% year over year. Applying the national modality mix gives 47.1% mAbs, 30.1% siRNA and 22.8% novel modalities.

Scotland: Population-weighted contribution is approximately 8.0%, equivalent to about USD 39 million of 2025 value under the same analytical allocation. Population increased 0.7% in 2024; the national sector split remains 47.1%/30.1%/22.8% for mAbs/siRNA/novel modalities where local therapeutic-mix data are unavailable.

Wales: A population proxy places Wales near 4.6%, or approximately USD 22 million in 2025. Population increased 0.6%; applying the national mix allocates approximately 47.1% to mAbs and 30.1% to siRNA, with 22.8% in novel modalities.

Northern Ireland: The corresponding proxy is approximately 2.8%, or USD 14 million of 2025 value, with population expanding 0.4%. National modality proportions imply 47.1% mAbs, 30.1% siRNA and 22.8% novel modalities. PCSK9-specific production-unit data are not publicly disclosed for any of the four countries.

Top players in United Kingdom PCSK9-Targeted Therapy Market

1. Novartis
2. Amgen
3. Sanofi
4. Regeneron Pharmaceuticals
5. Merck & Co.
6. AstraZeneca
7. Eli Lilly and Company
8. Verve Therapeutics
9. LIB Therapeutics
10. Alnylam Pharmaceuticals
11. Ionis Pharmaceuticals

Top Two Companies

• Novartis:Company-level UK value share is not disclosed in the supplied dataset; its modality-linked position is represented by the siRNA category, which accounted for 30.1% of 2025 value. Inclisiran benefits from the NHS population-health framework initially targeting 300,000 patients over 3 years, potentially expanding toward 500,000. The 284-mg therapy uses long-interval maintenance dosing, differentiating it from every-2-week antibodies. This access architecture positions Novartis strongly in community-based lipid management, although the 30.1% figure is a modality share rather than a verified company revenue share.
• Amgen:Evolocumab positions Amgen within the mAb category, which represented 47.1% of supplied 2025 value and rises at 10.91% CAGR through 2034. The 47.1% is the total mAb pool shared with competing antibody products and therefore must not be interpreted as Amgen’s company-specific UK share. Amgen’s established injectable platform competes against the 30.1% siRNA pool and emerging oral/gene-editing technologies. Competitive pressure is increasing as oral candidates deliver approximately 50%–60% LDL-C reductions and VERVE-102 has demonstrated up to 62% LDL-C reduction after one infusion.

Recent Developments in United Kingdom PCSK9-Targeted Therapy Market

• 2026:Lilly reported VERVE-102 reductions of up to 88% in PCSK9 and 62% in LDL-C across 35 Phase 1b participants, with durability up to 18 months.
• 2026:England’s community prescription volume reached 1.30 billion items in 2025/26, up 3%, while spending increased 4% to £11.6 billion.
• 2025:Merck’s Phase 3 enlicitide programme reported 55.8% LDL-C reduction at week 24 and 59.7% in post-hoc analysis, with ≥97% adherence.
• 2025:AstraZeneca reported a 50.7% LDL-C reduction at 12 weeks with once-daily 30-mg AZD0780 added to statin therapy.
• 2025:Lilly agreed to acquire Verve Therapeutics for up to USD 1.3 billion, strengthening its one-time cardiovascular gene-editing pipeline.

Research Methodology

The assessment uses 2022–2024 as historical years, 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast horizon. Supplied numerical tables remain the primary source for market valuation, segment contribution and CAGR; external NHS, NICE, ONS and company/trial sources support clinical, demographic and operating context. The supplied modality total of USD 540.62 million in 2026 versus the indication total of USD 540.66 million differs by USD 0.04 million, while 2034 totals of USD 1,221.68 million and USD 1,222.76 million differ by USD 1.08 million; both source values are preserved rather than reconciled through alteration.